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Abstract
The addition of recombinant rat interleukin-5 (IL-5), which was purified from the hemolymph of silkworm Bombyx mori
larvae infected with IL-5-expressing recombinant virus, to cultures of rat bone marrow cells resulted in an increase in the
number of Luxol-fast-blue staining eosinophils in a time- and concentration-dependent manner. After 6 days culture with 100
pM recombinant rat IL-5, more than 90% of the bone marrow cells were eosinophil. The contents of major basic protein
(MBP) in the bone marrow cells determined by Western blot analysis using a polyclonal antibody to rat MBP were also
increased by recombinant rat IL-5 (100 pM). Furthermore, intravenous injections of recombinant rat IL-5 twice a day for six
consecutive days increased the population of eosinophils in peripheral blood cells and in bone marrow cells. These findings
indicate that rat IL-5 induces terminal differentiation and proliferation of progenitor cells to mature eosinophils in
rats. ß 2000 Elsevier Science B.V. All rights reserved.
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1. Introduction
Eosinophils are suggested to play important roles
in the pathogenesis of allergic in£ammation such as
bronchial asthma and atopic dermatitis [1^4]. In pa-
tients su¡ering from asthma, the number of eosino-
phils in bone marrow and peripheral blood and at
the in£ammatory site is increased [5^8]. At the in-
£ammatory site, in¢ltrating eosinophils release vari-
ous cytokines including interleukin-1 (IL-1), IL-4,
IL-8, IL-10 and interferon-Q, regulated upon activa-
tion in normal T cells expressed and secreted
(RANTES) and macrophage in£ammatory protein-
1K [9] and mediators such as leukotriene C4 [10^
12], platelet-activating factor [13,14] and granule pro-
teins including major basic protein (MBP), eosino-
phil cationic protein, eosinophil-derived neurotoxin
and eosinophil peroxidase [15^17], resulting in the
tissue damage and bronchial hyperresponsiveness
[12,14^17].
IL-5 is produced mainly by activated T cells and
mast cells [18]. In humans, IL-5 shows various bio-
logical activities such as eosinophil di¡erentiation
factor (EDF) activity [19^22] and eosinophil surviv-
al-enhancing activity [23]. The terminal di¡erentia-
tion and the proliferation of progenitor cells to ma-
ture eosinophils are induced by EDF activity of IL-5
[19^22,24,25], resulting in the increase in the number
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of eosinophils in allergic in£ammation [26^28]. Re-
cently, we have prepared recombinant rat IL-5 from
the hemolymph of silkworm Bombyx mori (B. mori)
larvae infected with cysteine proteinase-deleted virus
containing cDNA for rat IL-5 [25] and found that
recombinant rat IL-5 possesses EDF activity using
the methylcellulose-culture system [24] of rat bone
marrow cells [25]. However, in rat species, it has
not been clari¢ed whether the generation of rat eo-
sinophils is induced by rat IL-5 in vivo. In the
present study, we examined whether the recombinant
rat IL-5 increases the number of eosinophils in liquid
culture of rat bone marow cells and in vivo.
2. Materials and methods
2.1. Collection of rat bone marrow cells
Bone marrow cells were collected from thighbones
and shinbones of rats (Sprague^Dawley strain, male,
speci¢c pathogen-free, weighing 200^250 g, Charles
River Japan, Kanagawa, Japan) as described pre-
viouly [29]. The rats were treated in accordance
with procedures approved by the Animal Ethics
Committee of the Graduate School of Pharmaceuti-
cal Sciences, Tohoku University, Sendai, Japan.
After 3 washes with minimum essential medium al-
pha (KMEM, Gibco-BRL, Gaithersburg, MD,
USA), the bone marrow cells were used for the sub-
sequent experiments.
2.2. Culture of rat bone marrow cells
Bone marrow cells were suspended at 4U105 cells/
ml in KMEM containing 30% (v/v) fetal bovine se-
rum (FBS, Flow Laboratories, North Rydge, NSW,
Australia), 1% (w/v) bovine serum albumin (BSA,
Sigma, St. Louis, MO, USA) and the various con-
centrations of recombinant rat IL-5. The recombi-
nant rat IL-5 was prepared from the hemolymph of
silkworm B. mori larvae infected with cysteine pro-
teinase-deleted virus containing cDNA for rat IL-5
as described previously [25]. Five milliliters of the cell
suspension was poured into each well of a 6-well
culture dish (Corning, Corning, NY, USA) and in-
cubated at 37‡C in a humidi¢ed atmosphere of 5%
CO2 in air. After incubation, the cells were harvested
and the total number of cells that excluded Trypan
blue dye was determined using a hemocytometer. A
portion of the cells was smeared on a slide glass and
stained with Luxol-fast-blue (EM Science, Cherry
Hill, NJ, USA) and hematoxylin (Merck, Darmstadt,
Germany) to identify eosinophils and the percentage
of eosinophils was calculated. The total number of
eosinophils was then determined.
2.3. Immunoblotting for MBP
Rat MBP was detected by a modi¢cation of the
method described by Nittoh et al. [30]. After incuba-
tion for 3 and 6 days in the presence and absence of
recombinant rat IL-5 (100 pM), bone marrow cells
(1U105 cells) were boiled for 5 min in loading bu¡er
(31.25 mM Tris^HCl (pH 6.8), 1% (w/v) sodium do-
decylsulfate, 10% (v/v) glycerol, 5% (v/v) 2-mercap-
toethanol and 0.01% (w/v) bromophenol blue), ap-
plied to a 15% (w/v) polyacrylamide gel and
subjected to electrophoresis at 125 V for 2 h. After
electrophoresis, proteins in the gel were transferred
onto a nitrocellulose membrane (Schleicher and
Schuell, Dassel, Germany). Non-speci¢c binding sites
were blocked by incubation for 1 h at room temper-
ature in Block Ace (Dainippon, Osaka, Japan). The
membrane was then incubated for 12 h at 4‡C with
rabbit anti-MBP antibody [30] at a concentration of
0.1 Wg/ml. After 3 washes, the membrane was incu-
bated at 4‡C for 3 h with a 1:5,000 dilution of bio-
tinylated anti-rabbit IgG (Vector Laboratories, Bur-
lingame, CA, USA). The reaction products were
incubated for 30 min at room temperature with
ABC reagent (Vector Laboratories) and visualized
by ECL Systems (Amersham Pharmacia Biotech,
Buckinghamshire, UK). The membrane was exposed
to a Kodak X-Omat AR ¢lm (Eastman Kodak, Ro-
chester, NY, USA) for 5 min at room temperature.
2.4. Detection of eosinophils in peripheral blood and
bone marrow of rats
Rats (Sprague^Dawley strain, male, speci¢c patho-
gen-free, weighing 200^250 g, Charles River Japan)
received intravenous injections of the sterilized saline
containing 0.01% (w/v) BSA in the presence or ab-
sence of 10 nM recombinant rat IL-5 at a dose of
10 pmol/kg at intervals of 12 h for 6 days. Control
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rats received the saline solution without recombinant
rat IL-5 in the same way. Bone marrow cells from
thighbones and shinbones and peripheral blood were
collected 12 h after the last injection of the recom-
binant rat IL-5. The percentage of eosinophils in
bone marrow cells and in white blood cells was iden-
ti¢ed after staining with Luxol-fast-blue and hema-
toxylin.
2.5. Statistical analysis
The statistical signi¢cance of the results was ana-
lyzed by Dunnett’s test for multiple comparison.
3. Results
3.1. Time-course of the e¡ects of recombinant rat
IL-5 on the number of eosinophils in rat bone
marrow cells
We examined whether the recombinant rat IL-5
increases the number of eosinophils. Before incuba-
tion, the number of eosinophils in 2.0U106 bone
marrow cells was (10.6 þ 1.1)U104 cells (Fig. 1).
When the bone marrow cells were incubated in the
absence of recombinant rat IL-5, the number of total
cells and eosinophils was decreased time-dependently
(Fig. 1A). After 6 days incubation of the bone mar-
row cells in the absence of recombinant rat IL-5, the
number of total cells and eosinophils was
(11.8 þ 1.0)U104 and (0.6 þ 0.1)U104 cells, respec-
tively (Fig. 1A). In contrast, the number of eosino-
Fig. 1. Time-course of the e¡ects of recombinant rat IL-5 on
the number of eosinophils in bone marrow cells. Bone marrow
cells (2U106 cells) were incubated at 37‡C for the periods indi-
cated in 5 ml of KMEM supplemented with 30% FBS and 1%
BSA in the presence (B) or absence (A) of recombinant rat IL-
5 (100 pM). After incubation, the number of total cells (open
columns) was counted using a hemocytometer and the total
number of eosinophils (closed columns) was calculated as fol-
lows: total number of eosinophils = (number of total cells)U(eo-
sinophils (%))U0.01. Values are the means from 6 samples with
S.E.M. shown by vertical bars. Statistical signi¢cance:
**P6 0.01, ***P6 0.001 versus number of eosinophils before
incubation (day 0).
Fig. 2. E¡ects of recombinant rat IL-5 on the number of eosin-
ophils in bone marrow cells. Bone marrow cells (2U106 cells)
were incubated at 37‡C for 6 days in 5 ml of KMEM supple-
mented with 30% FBS and 1% BSA containing the indicated
concentrations of recombinant rat IL-5. After incubation for
6 days, the number of total cells was counted using a hemocy-
tometer and the total number of eosinophils was calculated as
follows: total number of eosinophils = (number of total cells)
U(eosinophils (%))U0.01. Values are the means from 6 samples
with S.E.M. shown by vertical bars. Statistical signi¢cance:
*P6 0.05, **P6 0.01, ***P6 0.001 versus before incubation
(day 0); ##P6 0.01, ###P6 0.001 versus after 6 days incubation
without rat IL-5.
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phils increased time-dependently by 100 pM re-
combinant rat IL-5 (Fig. 1B). A signi¢cant increase
in the number of eosinophils was observed from
3 days after incubation. In the presence of recombi-
nant rat IL-5, the number of total cells decreased up
to 3 days, but re£ecting the increase in the number of
eosinophils, the number of total cells did not de-
crease after 3 days (Fig. 1B). After 6 days incubation
of the bone marrow cells in the presence of recombi-
nant rat IL-5, the number of total cells and eosino-
phils was (69.5 þ 2.6)U104 and (63.9 þ 3.9)U104
cells, respectively. More than 90% in rat bone mar-
row cells were eosinophils.
3.2. E¡ects of recombinant rat IL-5 on the number of
eosinophils in rat bone marrow cells
When rat bone marrow cells were incubated at
37‡C for 6 days in the absence of recombinant rat
IL-5, the number of eosinophils decreased compared
with that before incubation (Fig. 2). In contrast, the
presence of recombinant rat IL-5 increased the num-
ber of eosinophils in a concentration-dependent man-
ner (Fig. 2). A signi¢cant increase in the number of
eosinophils was observed at 10 and 100 pM recombi-
nant rat IL-5 (Fig. 2). Microscopic observation also
revealed that recombinant rat IL-5 (100 pM) in-
creases the number of eosinophils in bone marrow
cells when examined 6 days after incubation (Fig. 3).
These ¢ndings indicate that recombinant rat IL-5
increases the number of eosinophils in rat bone mar-
row cells in vitro.
Fig. 3. Microscopic observations of the bone marrow cells.
Bone marrow cells after 6 days incubation in the presence (B)
or absence (A) of recombinant rat IL-5 (100 pM). The cells
were smeared and stained with Luxol-fast-blue and hematoxy-
lin. Eosinophils are shown by arrowheads. Magni¢cation U160.
Fig. 4. Detection of MBP in cultured bone marrow cells. Bone
marrow cells (2U106 cells) were incubated at 37‡C for the peri-
ods indicated in 5 ml of KMEM supplemented with 30% FBS
and 1% BSA in the presence or absence of recombinant rat IL-
5 (100 pM). The cells were lysed and MBP contents in 1U105
cells were detected by immunoblotting (upper panel). The MBP
was quanti¢ed by scanning densitometry and the density of
MBP in the cells is shown in the lower panel. The mean density
at day 0 is set to 100. Values are the means from 3 samples
with S.E.M. shown by vertical bars. Statistical signi¢cance:
***P6 0.001 versus before incubation (day 0).
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3.3. Detection of rat MBP in cultured bone marrow
cells
We analyzed whether the increase in the number of
eosinophils is accompanied with the expression of
MBP in bone marrow cells. When the bone marrow
cells were incubated for 6 days in the absence of
recombinant rat IL-5, the content of MBP in the
bone marrow cells was decreased compared with
that in the cells before incubation (Fig. 4). In con-
trast, the content of MBP was signi¢cantly increased
by 100 pM recombinant rat IL-5, 3 and 6 days after
incubation (Fig. 4). These ¢ndings indicate that the
increase in the number of eosinophils by recombi-
nant rat IL-5 is accompanied with the expression of
MBP.
3.4. E¡ects of intravenous injection of recombinant rat
IL-5 on the population of eosinophils in peripheral
blood and bone marrow
To analyze whether the recombinant rat IL-5 in-
duces eosinophilia, rats received intravenous injec-
tions of recombinant rat IL-5 at a dose of 10
pmol/kg at intervals of 12 h for 6 days and the per-
centage of eosinophils in peripheral blood cells and
in bone marrow cells were determined. When rats
were injected intravenously with saline solution con-
taining no recombinant rat IL-5, the percentage of
eosinophils in peripheral blood cells and in bone
marrow cells did not signi¢cantly change when com-
pared with that before injection of IL-5 (Fig. 5). In
contrast, the repeated injection of recombinant rat
IL-5 increased the percentage of eosinophils in pe-
ripheral blood cells and in bone marrow cells (Fig.
5). A signi¢cant increase in the percentage of eosin-
ophils in peripheral blood cells and in bone marrow
cells was also observed 3 days after injection (data
not shown). These ¢ndings indicate that the repeated
intravenous injection of recombinant rat IL-5 indu-
ces eosinophilia in rats.
4. Discussion
It is reported that human IL-5 and mouse IL-5
induce the generation of mature eosinophils from
precursor cells in vitro in each species [19^22]. The
present paper is the ¢rst to report that recombinant
rat IL-5 [25] generates mature eosinophils from pre-
cursor cells in rats in vitro and in vivo.
Rats are useful animals for the analysis of allergic
in£ammation [25,30^34]. Nittoh et al. [30] reported
that the intraperitoneal injection of Ascaris suum
Fig. 5. E¡ects of recombinant rat IL-5 on the population of eo-
sinophils in peripheral blood cells and in bone marrow cells.
Recombinant rat IL-5 was injected intravenously at a dose of
10 pmol/kg at intervals of 12 h for 6 days and the number of
eosinophils in peripheral blood cells (A) and in bone marrow
cells (B) was counted 12 h after the last injection of recombi-
nant rat IL-5. Percentage of eosinophils was calculated as fol-
lows: eosinophils (%) = (number of cells stained with Luxol-
fast-blue/number of cells stained with hematoxylin)U100. Val-
ues are the means from 5^6 rats with S.E.M. shown by vertical
bars. Statistical signi¢cance: **P6 0.01, ***P6 0.001 versus
before injection (day 0); ##P6 0.01, ###P6 0.001 versus corre-
sponding 6 day control.
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antigen to the immunized rats increases the number
of eosinophils in peripheral blood and in bone mar-
row. Underwood et al. [31] showed that the inhala-
tion of the antigen ovalbumin causes the expression
of IL-5 mRNA in lung tissue and the in£ux of eo-
sinophils into lung tissue and airway lumen. Re-
cently, we [25] reported that recombinant rat IL-5
induces eosinophilic colony formation in rat bone
marrow cells and enhances survival of eosinophils.
Therefore, in rat species, it is very possible that IL-
5 contributes to eosinophilia as in human and mouse
species [5^8,26^28]. To prove this possibility, we ex-
amined the e¡ect of recombinant rat IL-5 on the
generation of eosinophils in vitro and in vivo. Pre-
liminary experiments revealed that rat neutrophils
and macrophages isolated from the peritoneal cavity
[35,36] are not stained with Luxol-fast-blue which
speci¢cally binds to granule proteins of human eo-
sinophils [37]. Therefore, in this paper, we identi¢ed
rat eosinophils by staining with Luxol-fast-blue. As
shown in Fig. 4, the content of rat MBP determined
by using the polyclonal antibody to rat MBP [30]
was increased by recombinant rat IL-5, in parallel
with the increase in the number of Luxol-fast-blue-
positive cells in bone marrow cells (Fig. 1). Because
MBP is a speci¢c granule protein in eosinophils [38],
it is strongly indicated that the Luxol-fast-blue-pos-
itive cells in rats are eosinophils and recombinant rat
IL-5 induces generation of eosinophils from progen-
itor cells in vitro.
It is reported that IL-5 and granulocyte colony-
stimulating factor (G-CSF) di¡erentiate and prolifer-
ate the stem cells to eosinophils in humans and in
mice [20,24]. Ema et al. [39] reported that, in hu-
mans, IL-3 and G-CSF di¡erentiate CD33 CD34
stem cells to CD33 CD343 stem cells, while IL-5
di¡erentiates and proliferates only CD33 CD343
stem cells to mature eosinophils. These reports sug-
gest that IL-5 supports the late-stage di¡erentiation
of eosinophils. In the present study, we observed that
the number of eosinophils in the bone marrow cells
was increased by recombinant rat IL-5 (Figs. 1^3).
Therefore, it is suggested that CD33 CD343 stem
cells in rat bone marrow cells might have responded
to the recombinant rat IL-5. Yamaguchi et al. [40]
reported that the expression of MBP gene in human
eosinophils is regulated by several transcription fac-
tors including GATA1, GATA2, C/EBPK and C/
EBPL. In C/EBPK-de¢cient mice, the development
of eosinophils and the expression of G-CSF receptors
are impaired [41]. Mu«ller et al. [42] also showed that
NF-M, a chicken homolog of C/EBPL, induces
eosinophil di¡erentiation in human hematopoietic
progenitor cells. The stimulation of eosinophils by
IL-5, GM-CSF or LTB4 activates the JAK/STAT
pathway, the p44/42 MAP kinases pathway or the
PI 3-kinase/Akt pathway, but the activation of p44/
42 MAP kinases is not related to the eosinophil sur-
vival, aggregation, arachidonic acid release and
H2O2 generation ([43,44], Ishihara et al., submitted
for publication). However, transcription factor C/
EBPL is activated through the p44/42 MAP kinase
pathway in NIH-3T3 cells [45]. Therefore, it is pos-
sible that the activation of p44/42 MAP kinase is
essential for the IL-5-induced di¡erentiation of pro-
genitor cells to eosinophils. Further studies are re-
quired to clarify in detail the signal transduction
pathway leading to di¡erentiation and proliferation
of progenitor cells to eosinophils by IL-5.
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